Ordenar per
Keyphrases
Hepatitis B Virus
72%
Hepatitis delta Virus
48%
Hepatitis C Virus
46%
Chronic Hepatitis B
38%
Cirrhosis
29%
Ribavirin
29%
Hepatitis B Surface Antigen (HBsAg)
28%
Hepatitis B
27%
Hepatitis D Virus
26%
Hepatitis E Virus
26%
Virus
24%
Delta Infection
24%
Hepatitis C Virus Infection
24%
Spain
22%
Hepatitis B Virus DNA
22%
Sofosbuvir
20%
Chronic Hepatitis D
20%
Liver Transplantation
20%
Virus RNA
20%
Hepatitis B e Antigen (HBeAg)
20%
Next-generation Sequencing
19%
Hepatitis D
19%
Hepatitis C
19%
Acute Hepatitis
18%
Ultra-deep Pyrosequencing
17%
Linkage to Care
17%
Acute Hepatitis E
16%
Chronic delta Hepatitis
16%
Superinfection
16%
Hepatitis B Immunoglobulin
16%
Entecavir
16%
B Hepatitis
15%
Direct-acting Antivirals
14%
Hepatitis
14%
Quasispecies
14%
Serum Samples
14%
Resistance-associated Substitutions
14%
Sustained Virological Response
14%
Velpatasvir
14%
Tenofovir Disoproxil Fumarate
13%
Hepatitis C Virus Genotypes
13%
Virus Quasispecies
13%
Hepatitis B Virus Infection
13%
Anti-HBc
13%
Genotype
12%
HDAg
12%
Clinical Practice
12%
Quasispecies Complexity
12%
Chronic Hepatitis
12%
Hepatocellular Carcinoma
11%
Immunology and Microbiology
Hepatitis B Virus
100%
Hepatitis B
72%
Hepatitis Delta Virus
60%
Infection
54%
Hepatitis D
40%
Hepatitis C Virus
40%
Ribonucleic Acid
29%
Hepatitis B Antigen
26%
HBsAg
26%
Hepatitis B(e) Antigen
26%
Hepatitis C
25%
Virus
23%
Quasispecies
23%
Viral Replication
21%
Hepatitis E Virus
20%
Viral Disease
20%
DNA Virus
20%
Next Generation Sequencing
19%
Virus Genome
18%
Liver Transplantation
16%
Pyrosequencing
16%
Amino Acid
12%
Hepatitis Virus
12%
Human Immunodeficiency Virus
12%
Hepatitis E
11%
Epitope
10%
Superinfection
10%
Prevalence
10%
Amino Acid Substitution
10%
Real Time Polymerase Chain Reaction
9%
Immunoglobulin M
9%
Virus Quasispecies
9%
Coinfection
9%
Haplotype
8%
Hepatitis B Immune Globulin
8%
Sofosbuvir
8%
Cytotoxic T-Cell
7%
Cladistics
7%
Hepatitis B Core Antibody
7%
Replication
7%
Codon
7%
Virus Resistance
7%
NS5A Inhibitors
7%
Tenofovir
7%
Viral Quasispecies
6%
NS5B
6%
Blood Plasma
6%
Dynamics
5%
Hepatitis C Virus Genotype 1
5%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis B Virus
48%
Delta Agent Hepatitis
44%
Hepatitis B
43%
Infection
38%
Chronic Hepatitis B
35%
Liver Cirrhosis
32%
Hepatitis B Antigen
29%
Hepatitis Delta Virus
27%
Hepatitis C Virus
26%
Hepatitis C
23%
Ribavirin
23%
Acute Hepatitis
21%
Hepatitis E Virus
20%
HIV
18%
Hepatitis B(e) Antigen
18%
Chronic Hepatitis
18%
Sofosbuvir
17%
Virus RNA
17%
Entecavir
15%
Immunoglobulin M
14%
Chronic Hepatitis C
13%
Virus Infection
13%
Hepatitis B Core Antibody
13%
Hepatitis E
12%
Antiviral Drug
12%
Tenofovir Disoproxil
12%
Diseases
11%
Tenofovir
11%
Superinfection
11%
Mixed Infection
10%
Sofosbuvir Plus Velpatasvir Plus Voxilaprevir
10%
Virus DNA
10%
Velpatasvir
10%
Liver Disease
9%
Acute Hepatitis B
9%
Liver Cell Carcinoma
9%
Virus Hepatitis
8%
Liver Injury
8%
Recurrent Disease
8%
Drug Dependence
8%
Hepatitis C Virus Genotype 3
8%
Prospective Study
8%
Peginterferon
8%
Adverse Event
7%
Antivirus Agent
7%
Hepatitis B Antibody
7%
Chronic Liver Disease
6%
Chronic Active Hepatitis
6%
Tenofovir Alafenamide
5%
Aminotransferase
5%
